Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Sapphire Therapeutics, Inc. |
---|---|
Information provided by: | Sapphire Therapeutics, Inc. |
ClinicalTrials.gov Identifier: | NCT00219817 |
Anorexia and weight loss are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite. RC-1291 HCl, by virtue of its ghrelin like activity and Growth Hormone releasing effects may have a dual role in the reversal of cancer induced anorexia and weight loss. This study will test the safety and efficacy of RC-1291 in the treatment of cancer patients with anorexia and weight loss.
Condition | Intervention | Phase |
---|---|---|
Cancer Cachexia |
Drug: RC-1291 HCl |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, New York | |
Columbia University Medical Center | |
New York, New York, United States, 10032 | |
United States, Texas | |
Michael E. DeBakey Veterans Affairs Medical Center | |
Houston, Texas, United States, 77030 | |
United States, Virginia | |
Cancer Outreach Associates | |
Abingdon, Virginia, United States, 24211 |
Study Director: | Karen Kumor, MD | Sapphire Therapeutics |
Study ID Numbers: | RC-1291-203 |
Study First Received: | September 12, 2005 |
Last Updated: | October 23, 2006 |
ClinicalTrials.gov Identifier: | NCT00219817 |
Health Authority: | United States: Food and Drug Administration |
Anorexia Cachexia |
Body Weight Signs and Symptoms Weight Loss Body Weight Changes |
Anorexia Cachexia Emaciation |